BlossomHill Therapeutics, Inc.

NasdaqGS:BLSM Stock Report

Market Cap: US$495.8m

BlossomHill Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:BLSM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Aug 26BuyUS$11,200Jason KeyesIndividual700US$16.00
10 Aug 26BuyUS$96,000John SchmidIndividual6,000US$16.00
10 Aug 26BuyUS$5,000,000Cormorant Asset Management, LPCompany312,500US$16.00
10 Aug 26BuyUS$74,700Vincent LiptakIndividual4,700US$16.00
10 Aug 26BuyUS$10,000,000OrbiMed Advisors LLCCompany625,000US$16.00

Insider Trading Volume

Insider Buying: BLSM insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BLSM?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,714,1175.59%
VC/PE Firms2,089,2796.82%
Institutions3,206,62510.5%
Individual Insiders3,552,19911.6%
Hedge Funds3,614,03411.8%
General Public16,467,40653.7%

Dilution of Shares: BLSM only recently listed within the past 12 months

Top Shareholders

Top 15 shareholders own 46.26% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.8%
Cormorant Asset Management, LP
3,614,034US$58.5m0%2.42%
6.82%
OrbiMed Advisors LLC
2,089,279US$33.8m0%0.45%
5.59%
The Li and Cui Family Trust
1,714,117US$27.7m0%no data
4.87%
Vivo Capital, LLC
1,493,740US$24.2m0%1.74%
3.7%
Janus Henderson Group Ltd.
1,134,361US$18.4m0%0.01%
3.48%
Yishan Li
1,067,121US$17.3m0%no data
3.48%
Jingrong Cui
1,067,121US$17.3m0%no data
3.48%
Jingrong Jean Cui
1,067,121US$17.3m0%no data
1.89%
Brahma Capital
578,524US$9.4m0%no data
0.41%
Li Yishan
124,779US$2.0m0%no data
0.36%
Vincent Liptak
111,412US$1.8m0%no data
0.29%
Sheila Gujrathi
90,160US$1.5m0%no data
0.058%
Geoff Oxnard
17,785US$287.8k0%no data
0.02%
John Schmid
6,000US$97.1k0%no data
0.0023%
Jason Keyes
700US$11.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/16 02:30
End of Day Share Price 2026/08/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BlossomHill Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.